ATOM-1
LIVE

Serial Number

98355762

Owner

Atomic AI, Inc.

Attorney

Aaron D. Hendelman

Filing Date

Jan 12, 2024

Add to watchlist:

No watchlists yet
View on USPTO

ATOM-1 Trademark

Serial Number: 98355762

ATOM-1 is a trademark filed by Atomic AI, Inc. on January 12, 2024. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Atomic AI, Inc.

151 Oyster Point Blvd, 3rd Floor
South San Francisco, CA 94080

Entity Type: 03

Trademark Details

Filing Date

January 12, 2024

Registration Date

Not Registered

Published for Opposition

September 17, 2024

Goods & Services

Providing online non-downloadable computer software platforms for use in developing therapies for the modification of RNA expression and alteration of RNA translation, used in the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; providing online non-downloadable computer software platforms for use in automated design and development of biomolecules for medical and scientific use, for use in the manufacture of biosensors, agriculture, synthetic biological research, laboratories and environmental safety and testing; providing online non-downloadable computer software platforms for use in drug design and development featuring machine-learning algorithms and lab automation tools; research and development of pharmaceuticals, namely, therapies for the modification of RNA expression and alteration of RNA translation, used in the treatment of cancers and autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; research and development in the fields of biotechnology, DNA, RNA, molecules and proteins; automated design and development of biomolecules for medical and scientific use, for use in the manufacture of biosensors, agriculture, synthetic biological research, laboratories and environmental safety and testing; drug design and development featuring machine-learning algorithms and lab automation tools; developing customized software in the field of drug design and development

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 13, 2026 EXRA
SOU EXTENSION 3 GRANTED
May 12, 2026 EX3G
SOU EXTENSION 3 FILED
May 12, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
May 12, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 2 GRANTED
Sep 5, 2025 EX2G
SOU EXTENSION 2 FILED
Sep 4, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 4, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 8, 2025 EXRA
SOU EXTENSION 1 GRANTED
Feb 8, 2025 EX1G
SOU EXTENSION 1 FILED
Feb 8, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 7, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 12, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 17, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 17, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 28, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 15, 2024 CNSA
ASSIGNED TO EXAMINER
Aug 9, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2024 NWOS
NEW APPLICATION ENTERED
Jan 12, 2024 NWAP